Free Trial

Accelerate Diagnostics Q1 2024 Earnings Report

Accelerate Diagnostics logo
$1.11 +0.04 (+3.74%)
(As of 05:22 PM ET)

Accelerate Diagnostics EPS Results

Actual EPS
-$0.88
Consensus EPS
-$0.72
Beat/Miss
Missed by -$0.16
One Year Ago EPS
N/A

Accelerate Diagnostics Revenue Results

Actual Revenue
$2.92 million
Expected Revenue
$3.00 million
Beat/Miss
Missed by -$80.00 thousand
YoY Revenue Growth
N/A

Accelerate Diagnostics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Forced out of retirement by these trades (Ad)

You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changed

Make sure to check out Gamma Pockets HERE while it’s still widely available 

Accelerate Diagnostics Earnings Headlines

70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!
Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.
Accelerate Diagnostics Reports Key Advances Amid Financial Challenges
See More Accelerate Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Accelerate Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accelerate Diagnostics and other key companies, straight to your email.

About Accelerate Diagnostics

Accelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

View Accelerate Diagnostics Profile

More Earnings Resources from MarketBeat